蔡乐斌 陶娜 郭文

[摘要] 目的 观察在拉米夫定耐药慢性乙型病毒性肝炎(CHB)患者中应用恩替卡韦治疗的临床效果分析。方法 方便选取在该院近期(2015年7月—2018年2月时期)收治拉米夫定耐药CHB患者总计60例,均采取恩替卡韦治疗6个月,并对患者进行4个月的有效随访。对照治疗后不同时间段的临床效果,不良反应发生率及肝功能、乙型肝炎病毒脱氧核糖核酸(HBV -DNA)变化。 结果 患者入组后治疗第1个月显效率为53.33%,有效率为16.67%,总有效率为70.00%;治疗第2个月显效率为68.33%,有效率为10.00%,总有效率为78.33%;治疗第3个月显效率为76.67%,有效率为8.33%,总有效率为80.00%;治疗第4个月显效率为81.67%,有效率为8.33%,总有效率为90.00%(P=0.001)。治疗前患者肝功能指标及HBV -DNA指标水平较高,治疗后肝功能指标及HBV -DNA指标水平较治疗前明显下降,差异有统计学意义(P=0.002)。 结论 对于拉米夫定耐药CHB患者患者而言,采取恩替卡韦治疗,可获得较好的临床治疗效果,并发症较低且可明显改善患者肝功能,降低HBV-DNA表达量,效果理想。
[关键词] 恩替卡韦;拉米夫定耐药;慢性乙型肝炎;临床效果
[中图分类号] R512.6+2 [文献标识码] A [文章编号] 1674-0742(2019)04(c)-0122-03
[Abstract] Objective To observe the clinical effect of entecavir in patients with lamivudine-resistant chronic hepatitis B (CHB). Methods A total of 60 patients with lamivudine-resistant CHB treated with entecavir for 6 months in our hospital (July 2015 to February 2018) were convenient selected. The patients were followed up for 4 months. The clinical effects, incidence of adverse reactions, liver function and changes of hepatitis B virus deoxyribonucleic acid (HBV-DNA) at different time points after treatment were compared. Results One month after treatment. The marked effective rate was 53.33%, the effective rate was 16.67%, the total effective rate was 70.00%. Two months after treatment, the marked effective rate was 68.33%, the effective rate was 10.00%, the total effective rate was 78.33%. Three months after treatment, the marked effective rate was 76.67%, the effective rate was 8.33%, the total effective rate was 80.00%. Four months after treatment, the marked effective rate was 81.67%, the effective rate was 8.33% and the total effective rate was 90.00% (P=0.001). The level of liver function index and HBV-DNA index before treatment was high, and the level of liver function index and HBV-DNA index after treatment decreased significantly. The difference was statistically significant (P=0.002). Conclusion Entecavir is effective in the treatment of the patients with lamivudine-resistant CHB. It can improve liver function, reduce complications and the expression of HBV-DNA.
[Key words] Entecavir; Lamivudine resistance; Chronic hepatitis B; Clinical effect
病毒引起的傳染性疾病-乙型病毒性肝炎(HBV),可致肝脏衰竭、肝硬化以及肝癌等,临床在抗病毒治疗同时抑制纤维化,拉米夫定等为临床常用药物,且伴随着其应用的范围广,疗程长,逐渐出现了耐药[1]。据不完全统计,每100例拉米夫定疗程>4年患者中,约有70例出现由基因突变所产生拉米夫定耐药株,称为CHB患者中难治疗者[2]。恩替卡韦也是HBV常用药物,以耐药率低、抗病毒能力强、低不良反应使用[3]。但……